Sponsor Dossier
Generic Health
Sponsor Dossier for Generic Health. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTOS
- Brand: ALENDROBELL
- Brand: ALFENTANIL GH
- Brand: AMLODIPINE GH
- Brand: AMOXYCLAV GENERICHEALTH
- Brand: ANASTROZOLE-GH
- Brand: ARIPIPRAZOLE GH
- Brand: ATENOLOL
- Device (sponsor): Clinical chemistry hormone IVDs
About
Generic Health is an Australian Private Company with ABN 93110617859, incorporated in Victoria. The company is registered for GST and maintains active entity status. Generic Health operates under the trading name LUPIN au.
Portfolio
Generic Health has 63 brands on the ARTG, of which 53 are indexable and 52 carry a Product Information document. 39 brands are PBS-listed, 3 have a PBAC outcome on record, and 1 has an AusPAR on record. Notable brands include ACTOS, ALENDROBELL, ALFENTANIL GH, AMLODIPINE GH, AMOXYCLAV GENERICHEALTH, ANASTROZOLE-GH, ARIPIPRAZOLE GH, ATENOLOL, ATORVASTATIN GH, ATOVAQUOPRO, Bisoprolol, BOSENTAN GH.
Therapeutic focus
— Cardiology: 14 brands — Psychiatry: 11 brands — Neurology: 6 brands — Infectious Disease: 5 brands — Endocrinology: 4 brands — Reproductive Health: 3 brands — Oncology: 3 brands — Pain Management: 3 brands — Musculoskeletal: 3 brands — Gastroenterology: 2 brands — Respiratory: 2 brands — Dermatology: 2 brands — Immunology: 2 brands — Hepatology: 1 brand — Rare Disease: 1 brand — Renal: 1 brand
PBS footprint
39 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-07-01, across 3 brands with a PBAC outcome on record. The latest AusPAR is 2023-10-17, across 1 brand with an AusPAR on record.